Comparison of Amikacin Lung Delivery With Two Nebulizers

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02538588

Enrollment

Registered

2015-09-02

Start date

2015-08-31

Completion date

2015-12-31

Last updated

2015-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Healthy

Keywords

Healthy Volunteers

Brief summary

Comparison between two modalities of nebulization.

Interventions

DEVICENebulizer 1

DEVICENebulizer 2

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

16 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Male healthy subjects * Cystic fibrosis

Exclusion criteria

* Kidney failure * No pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Total urinary concentration of amikacin	24 hours after the nebulization	Pharmacokinetic study of the urinary excretion of amikacin after nebulization

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026